DETERMINE is a cutting edge UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.
Benefits of becoming a partner
The DETERMINE trial enables the valuation of licensed targeted cancer drugs in unlicensed cancer indications.
As a commercial partner, you’ll benefit from:
- Novel, fast-track route to approval via the Cancer Drugs Fund (CDF) for drugs which prove effective
- Rich translational data package that can help optimise biomarker selection of patients
- Streamlined compassionate use requests into a structured access mechanism with associated data collection
- Dedicated Business Development contact and single contract to gain access to a trial with over 20 sites
Become a partner
We are seeking additional licensed targeted drugs from pharmaceutical and biotech companies and welcome enquiries about being included in the study. By submitting your enquiry you consent to a member of the DETERMINE team getting in touch regarding your enquiry.
Trial overview
DETERMINE is an umbrella, basket platform trial evaluating genotype-matched targeted agents outside of their licensed indications in rare adult, TYA and paediatric cancers with actionable genomic alterations.
Current treatment arms
There are currently 7 agents available across 5 arms in the DETERMINE trial, each targeting a specific genomic profile:
1. Alectinib (Alecensa)
2. Atezolizumab (Tecentriq)
3. Entrectinib (Rozlytrek)
4. Trastuzumab (Herceptin) and Pertuzumab (Perjeta)
5. Vemurafenib (Zelboraf) and Cobimetinib (Cotellic)
Recruitment
The trial aims to recruit 800-900 patients, through use of existing, national screening programmes, over the 5-year recruitment period. DETERMINE will be delivered through the Experimental Cancer Medicine Centres (ECMC) Network, which consists of 29 adult and paediatric sites across the UK.
Centre for Drug Development
As the trial sponsor, the Centre for Drug Development (CDD) will be responsible for all aspects of management and delivery of DETERMINE and will act as the central contact point for our partners.
Our team
Claire Hyder Business Development Executive, Cancer Research UK
Claire is a Business Development Executive for Clinical Collaborations at Cancer Research Horizons, Cancer Research UK’s commercialisation and innovation engine. Claire works closely with the Cancer Research UK Centre for Drug Development (CDD) and our commercial partners on the early clinical development of novel therapeutic agents.
Our initial collaborator
Roche
Our founding commercial partner
We’re proud to be working with Roche. Roche has provided 7 of their targeted therapies to be evaluated in the first instance.
What to expect
We're seeking further partners to contribute other licensed, targeted drugs and appropriate technologies to the trial
2. Meet with us
A member of the team will contact you to discuss the trial, potential collaboration opportunities and next steps.
3. Enter the trial
Upon approval from the DETERMINE trial team, you will join the trial as a DETERMINE partner. The trial is expected to recruit for 5 years with a 2-year follow-up period. Treatment arms will be added on a continual basis, with each arm to be evaluated through regular interim analyses.